BeyondSpring (BYSI) Other Non-Current Liabilities (2021 - 2026)
BeyondSpring's (BYSI) quarterly Other Non-Current Liabilities came in at $4.4 million in Q2 2026, up 16.84% year-over-year from $3.8 million in Q2 2025, and up 4.27% quarter-over-quarter from $4.2 million in Q1 2026.
Analysis
BeyondSpring (BYSI) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
BeyondSpring has disclosed Other Non-Current Liabilities across 6 years of filings, most recently posting $4.4 million for Q2 2026.
- In Q2 2026, Other Non-Current Liabilities rose 16.84% year-over-year to $4.4 million; the TTM figure through Jun 2026 stood at $4.4 million (up 16.84% YoY), while the FY2025 annual figure was $4.0 million, up 8.0% from the prior year.
- Other Non-Current Liabilities came in at $4.4 million for Q2 2026 at BeyondSpring, up from $4.2 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $4.4 million in Q2 2026 to a low of $692000.0 in Q2 2022.
- Average Other Non-Current Liabilities over 5 years is $3.6 million, with a median of $3.7 million recorded in 2023.
- Year-over-year, Other Non-Current Liabilities soared 416.36% in 2022 and decreased 0.51% in 2024.
- Over 5 years, Other Non-Current Liabilities stood at $3.7 million in 2022, then climbed by 1.2% to $3.7 million in 2023, then declined by 0.51% to $3.7 million in 2024, then climbed by 8.0% to $4.0 million in 2025, then increased by 11.03% to $4.4 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $4.4 million in Q2 2026, $4.2 million in Q1 2026, and $4.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn |
| 10 | BeyondSpring | 31.51 Mn | 31.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.42 Mn |
| Mar 31, 2026 | 4.24 Mn |
| Dec 31, 2025 | 3.98 Mn |
| Sep 30, 2025 | 3.84 Mn |
| Jun 30, 2025 | 3.78 Mn |
| Mar 31, 2025 | 3.71 Mn |
| Dec 31, 2024 | 3.69 Mn |
| Jun 30, 2024 | 3.61 Mn |
| Dec 31, 2023 | 3.71 Mn |
| Jun 30, 2023 | 3.53 Mn |
| Dec 31, 2022 | 3.66 Mn |
| Jun 30, 2022 | 692,000.00 |
| Dec 31, 2021 | 709,000.00 |
| Sep 30, 2021 | 1.26 Mn |
| Jun 30, 2021 | 341,000.00 |
| Mar 31, 2021 | 278,000.00 |